Immunic, Inc.’s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range

Immunic, Inc.'s Interim Dosing Analysis…

Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds

Ghent, Belgium, and Dresden, Germany…

Confo Therapeutics receives €1.7 million grant from VLAIO

Ghent, Belgium, 20 June 2019…

First patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

Mataró, Barcelona, Spain and Charleroi,…

Safety and immune stimulation data from an intranodal delivery of TriMix mRNA

Safety and immune stimulation data…

Appointment of Chief Financial Officer

Niel (Belgium), 29 May 2019…

Novadip presents data at 30th annual EURAPS Research Council Meeting

Novadip Biosciences presents data at…

EyeD Pharma successfully raises €28 million

Fund+, Qbic and a number…

Confo Therapeutics raises €30 million in Series A financing

Round led by BioGeneration Ventures…

Promethera Biosciences completes €39,7 million ($44,4 million) Series D financing

Proceeds will support ongoing clinical…